SlideShare a Scribd company logo
INTRAUTERINE GROWTH
RESTRICTION
PRESENTED AND PREPARED BY DR . DERAR I . I . ISMERAT
OBSTETRICS AND GYNECOLOGY RESIDENT DOCTOR AT AL-AHLI HOSPITAL
Intrauterine growth restriction (IUGR) is a poorly understood complication of pregnancy,
affecting up to 10% of live-born infants.
It is characterized as a rate of fetal growth less than normal for the gestational-age appropriate
growth potential Quantitatively, this poor fetal growth has been defined by the American
College of Obstetricians and Gynecologists as estimated fetal weight of <10th percentile for
gestational age, often times with ultrasound evidence of growth deceleration late in gestation or
abnormal Doppler indexes in the umbilical artery or middle cerebral artery.
Fetal growth restriction, (IUGR), is a common complication of pregnancy.
• Pathologic condition where there is a restriction of growth in utero, and the fetus does not attain
its full growth potential.
• Complicates ≈5-10% of pregnancies
• Third leading cause of perinatal mortality after anomalies
and prematurity
Perinatal mortality inversely proportional to percentile growth:
1.5% <10%
2.5% < 5th %
Correlation of birth weight percentile to
perinatal morbdity and mortalility
IUGR (Intrauterine Growth
Restriction)
SGA (Small for Gestation Age)
30% babies with birthweight <10th
percentile
70% babies with birthweight <10th
percentile
Growth restricted Not growth restricted
Constitutionally and anatomically
abnormal
Constitutionally small but
anatomically normal
↑ Obstetric/neonatal risk NO obstetric/neonatal risk
{Variable} Normal subcutaneous fat
• Stage I (Hyperplasia)
• - 4 to 20 weeks
• - Rapid mitosis
• - Increase of DNAcontent
• Stage II (Hyperplasia & Hypertrophy)
• - 20 to 28 weeks
• - Declining mitosis.
• - Increase in cell size.
• Stage III ( Hypertrophy)
- 28 to 40 weeks
- Rapid increase in cell size.
- Rapid accumulation of fat, muscle and connective tissue.
• 95% of fetal weight gain occurs
during last 20 weeks of gestations.
• 15 weeks = 5 grams/day
• 20 weeks = 10 grams/day
• 30 weeks = 25 grams/day
• 35 weeks = 35 grams/day
• 40 weeks = 15 grams/day
• May vary by race, gender, multiple gestation
Reduce fetal growth support..
EXTRINSIC CAUSES
Reduce fetal growth potential..
INTRINSIC CAUSES
PALCENTAL FACTORS
MATERNAL FACTORS
ANEUPLOIDY
INTRA UTERINE INFECTION
More morbidities and mortalities More long term effects
Infection
 CMV, Rubella, Toxoplasma gondii – severe IUGR
 Syphilis, Tuberculosis, Malaria, listeriosis
 Herpes simplex, chicken pox
Chromosomal abnormality
 Trisomy 18,13 –severe IUGR
 Trisomy 21
 Turner syndrome (45,XO(
 Klinefelter syndrome (47,XXY(
Congenital anomalies
 Congenital Heart diseases
 Anencephaly
• Maternal malnutrition
• Poor maternal weight gain
• Severe anemia
• Chronic hypoxemia
• Cardiovascular disease
• Drugs and teratogens
• Multiple pregnancy
• Antiphospholipid antibodies syndrome
• Placental infarction
• Placental abruption
• Twin-twin transfusion syndrome
• Placenta previa , circumvallate placenta
• Marginal or velamentous insertion of umbilical cord
: proposed in 1990 by the British epidemiologist
David Barker (b. 1939) that intrauterine growth retardation will increase :.
• Increased risk of adult metabolic syndrome
• Obesity
• Type 2 diabetes mellitus
• Coronary artery disease
• Stroke
• Up to 50% cognitive disability
• Increased risk of cerebral palsy
• <10th percentile at 8 years
• Early IUGR less likely to catch up
• Clinical assessment
• Ultrasonic measurement
• Doppler velocity
– Teen age
– High altitude
– Socioeconomic factor
– Smoking , Alcohol , Drugs
– Previous IUGR pregnancy history
– previous IUGR in family
Seldom elicited before 28 weeks of gestation:
. Failure of fetus and uterus to grow at the normal rate over a 4 week period;
.Uterine fundal height should be at least 2cm less than
expected for the length of gestation;
.Poor maternal weight gain;
. Diminished fetal movements.
Uterine fundal height
 Uterine fundus  symphysis Pubic
 Simple, Safe, Inexpensive for screening
 Between 18 and 30 weeks,
 the uterine fundal height in centimeters coincides with weeks of
gestation.
 If the measurement is more than 2 to 3 cm from the expected height or <
1oth percentile from normal curve, inappropriate fetal growth may be
suspected
 Inter-observer variations
 Obese patients
 Transverse lie
 Multiple gestation
 Polyhydramnios / Oligohydram
 Uterine fibroids
nios
Initial U/S at 16 to 20 weeks to establish gestational age
and identify anomalies and repeated at 32 to 34 weeks
to evaluate fetal growth
The measurements most commonly used to
measure and follow fetal growth are:
Biparietal Diameter
HeadCircumference
Femur Length
Abdominal Circumference
Used between 15-42 weeks. Normal ratio:
<36 weeks = 1:1
>36 weeks - ratio decreases as the AC increases.
Mild IUGR – Normal amniotic fluid
Severe IUGR – Oligohydramnios (AFI is ≤ 5) Incidence
40%
• Blood flowing through the umbilical arteries originates
from the fetus and enters the placenta.
• The flow of blood through the arteries is dependent upon the strength of the fetal heart contraction and the
health of the placenta.
• Blood returning from the placenta goes throughthe umbilical vein to the fetus.
• Doppler principle based on changes in sound waves related to the flow velocity of blood traveling
through these vessels.
• The umbilical artery was first used to study this flow velocity in in 1977.
• The umbilical arterial waveform usually has a "saw tooth" type pattern with flow always in the
forward direction
•The umbilical artery is evaluated by measuring the blood flow velocity at peak
systole (maximal contraction of the heart) and peak diastole (maximal relaxation of
the heart).
• These values are then
computed to derive a
ratio.
• As GA advances, increase blood flow at diastole means placenta
less resistant.
• In growth-retarded fetuses and fetuses developing intra- uterine distress, there is more
placental resistance and the umbilical artery blood velocity waveform usually changes
in a progressive manner.
• Increased resistance, absent end diastolic flow, reverse flow.
• Increasing RI values and S:D ratios if blood flow during diastole is decreased.
• Absent End Diastolic flow
• reversal of end diastolic flow (REDF)
• notching in late in pregnancy is an indicator of increased uterine
vascular resistance and impaired uterine circulation’
:
– characterized by absent or reversed end-diastolic flow
– associated with fetal growth restriction
A. Normal velocimetry pattern with an S/D ratio of <
3.0
B. The diastolic velocity approaching zero reflects
increased placental vascular resistance.
C. During diastole, arterial flow is reversed (negative
S/D ratio), which is an ominous sign
precede fetal demise
Hypothermia?
Hypoglycemia?
Or
Hypocalcemia?
decreased subcutaneous fat, increased
surface- volume ratio, decreased heat
production
decreased glycogen stores/
glycogenolysis/ gluconeogenesis
increased metabolic rate deficient
catecholamine release
Associated with perinatal stress, asphyxia,
prematurity
Prepregnancy: to prevent it by identifying risk factors and treat as necessary
(e.g. improve nutrition intake, stop smoking or alcohol, ASA in APA syndrome,
and Heparin in thrombophilias)
Antepartum: identify risk factors that can be changed. Fetal surveillance by
ultrasound (BPP) and fetal heart monitoring (Non-Stress Test). To decide on
timing and mode of delivery.
Near term
 Prompt delivery
Recommend delivery at 34 weeks or beyond if there is clinically significant
oligohydramnios
• Growth Restriction Intervention Trial
• Only published randomized trial to assess the timing of delivery of the early preterm (less
than 34 weeks of gestation) growth-restricted fetus.
• Randomized to either the early delivery group (delivery within 48 hours) or to the
expectant management group (with antepartum surveillance until it was felt that delivery
should not be delayed any longer)
• Betamethasone administration were the same in both groups
• Prospective Observational Trial to Optimize Pediatric Health in
Intrauterine Growth Restriction (IUGR) (PORTO STUDY)
• National prospective observational multicenter study
• Evaluate which sonographic findings were associated with perinatal
morbidity and mortality in pregnancies affected by growth restriction
(defined as estimated fetal weight (EFW) <10th centile)
• Am J Obstet Gynecol. 2013Apr;208(4)
• STUDY DESIGN:
• Over 1100 consecutive ultrasound-dated singleton pregnancies with EFW <10th centile
were recruited from January 2010 through June 2012.
• A range of IUGR definitions were used, including EFW orabdominal
circumference <10th, <5th, or <3rd centiles
• with or without oligohydramnios
• with or without abnormal umbilical arterial Doppler
• Adverse perinatal outcomes included intraventricular hemorrhage, periventricular
leukomalacia, hypoxic ischemic encephalopathy, necrotizing enterocolitis,
bronchopulmonary dysplasia, sepsis, and death
• Am J Obstet Gynecol. 2013Apr;208(4)
• RESULTS:
• N=1116 fetuses
• 312 (28%) were admitted to neonatal intensive care unit
• 58 (5.2%) were affected by adverse perinatal outcome including 8
mortalities (0.7%)
• The presence of abnormal umbilical Doppler was significantly associated with adverse outcome,
irrespective of EFW or abdominal circumference measurement.
• The only sonographic weight-related definition consistently associated with adverse outcome
was EFW <3rd centile (P = .0131), all mortalities had EFW <3rd centile.
• Presence of oligohydramnios was clinically important when combined with EFW <3rd centile
(P = .0066).
• Am J Obstet Gynecol. 2013 Apr;208(4)
• CONCLUSION:
• Abnormal umbilical artery Doppler and EFW <3rd centile were strongly
and most consistently associated with adverse perinatal outcome.
• Stricter IUGR cutoffs may be warranted and future studies should
comparing various definitions of IUGR and management strategies
• Management
• Serial US q 2-4 weeks is indicated
• Antenatal surveillance with umbilical artery Doppler velocimetry and
antepartum testing (NST,BPP)
• Delivery depends on the underlying etiology and estimated
gestational age
• Eunice Kennedy Shriver National Institute of Child Health and Human Development/Society
for Maternal-Fetal Medicine/American College of Obstetricians and Gynecologists Joint
Conference
• Dx fetal growth restriction:
• Delivery at 38 0/7–39 6/7 weeks of gestation isolated fetal growth restriction
• Delivery at 34 0/7–37 6/7 weeks of gestation in cases of fetal growth restriction with additional
risk factors for adverse outcome (eg, oligohydramnios, abnormal umbilical artery Doppler
velocimetry results, maternal risk factors, or co- morbidities)
• Delivery for fetal growth restriction before 34 weeks:
• Planned at a center with a neonatal intensive care unit and consultation
with a maternal–fetal specialist.
• Antenatal corticosteroids should be administered
• For cases in which delivery occurs before 32 weeks:
• Magnesium sulfate should be considered for fetal and neonatal
neuroprotection.
• Heads are disproportionately
large for their trunks and
extremities
• Facial appearance has been
likened to that of a “wizened
old man”.
• Long nails.
• Scaphoid abdomen
• Way of characterizing the relationship of height to mass for an individual.
• PI = 1000 x cubed root of Mass (kgs)
Height (cms)
• Typical values are 20 to 25.
• PI is normal in symmetric IUGR.
• PI is low in asymmetric IUGR
Iugr by dr derar ismerat

More Related Content

What's hot

Fetal Ventriculomegaly
Fetal VentriculomegalyFetal Ventriculomegaly
Fetal Ventriculomegaly
Nilesh Mhaske
 
Obstetrics doppler ultrasound
Obstetrics doppler ultrasoundObstetrics doppler ultrasound
Obstetrics doppler ultrasoundBharti Gahtori
 
Doppler in IUGR
Doppler in IUGRDoppler in IUGR
Doppler in IUGR
Sandeep Garg
 
Umblical & uterine artery Doppler
Umblical & uterine artery DopplerUmblical & uterine artery Doppler
Umblical & uterine artery Doppler
Aboubakr Elnashar
 
Multifetal pregnancy (Twins Pregnancy)
Multifetal pregnancy (Twins Pregnancy)Multifetal pregnancy (Twins Pregnancy)
Multifetal pregnancy (Twins Pregnancy)
nishma bajracharya
 
Fetal growth restriction:Evidence based management 2018
Fetal growth restriction:Evidence based management 2018Fetal growth restriction:Evidence based management 2018
Fetal growth restriction:Evidence based management 2018
Lifecare Centre
 
Non immune hydrops latest
Non immune hydrops latestNon immune hydrops latest
Non immune hydrops latest
Anita Srinivasan
 
preterm labour
preterm labourpreterm labour
preterm labour
NARENDRA MALHOTRA
 
Adolescent gynecology ucaya
Adolescent gynecology ucayaAdolescent gynecology ucaya
Adolescent gynecology ucaya
Greenville Health System
 
Doppler interpretation in pregnancy
Doppler interpretation in pregnancyDoppler interpretation in pregnancy
Doppler interpretation in pregnancy
Aboubakr Elnashar
 
First trimester ultrasound Dr. Muhammad Bin Zulfiqar
First trimester ultrasound Dr. Muhammad Bin ZulfiqarFirst trimester ultrasound Dr. Muhammad Bin Zulfiqar
First trimester ultrasound Dr. Muhammad Bin Zulfiqar
Dr. Muhammad Bin Zulfiqar
 
Single umbilical artery
Single umbilical arterySingle umbilical artery
Single umbilical arteryRitesh Mahajan
 
Overview of IUGR FGR
Overview of IUGR FGROverview of IUGR FGR
Overview of IUGR FGR
Dr.Laxmi Agrawal Shrikhande
 
Intrauterine growth restriction
Intrauterine growth restrictionIntrauterine growth restriction
Intrauterine growth restrictioncslonern
 
PLACENTA ACCRETA
PLACENTA ACCRETAPLACENTA ACCRETA
PLACENTA ACCRETA
paviarun
 
Antepartum and intrapartum foetal monitoring
Antepartum and intrapartum foetal monitoringAntepartum and intrapartum foetal monitoring
Antepartum and intrapartum foetal monitoringrajeev sood
 
First trimester scan
First trimester scanFirst trimester scan
First trimester scan
Archana Tandon
 

What's hot (20)

Fetal Ventriculomegaly
Fetal VentriculomegalyFetal Ventriculomegaly
Fetal Ventriculomegaly
 
Obstetrics doppler ultrasound
Obstetrics doppler ultrasoundObstetrics doppler ultrasound
Obstetrics doppler ultrasound
 
Doppler in IUGR
Doppler in IUGRDoppler in IUGR
Doppler in IUGR
 
Genetic sonogram
Genetic sonogramGenetic sonogram
Genetic sonogram
 
Umblical & uterine artery Doppler
Umblical & uterine artery DopplerUmblical & uterine artery Doppler
Umblical & uterine artery Doppler
 
Multifetal pregnancy (Twins Pregnancy)
Multifetal pregnancy (Twins Pregnancy)Multifetal pregnancy (Twins Pregnancy)
Multifetal pregnancy (Twins Pregnancy)
 
Fetal growth restriction:Evidence based management 2018
Fetal growth restriction:Evidence based management 2018Fetal growth restriction:Evidence based management 2018
Fetal growth restriction:Evidence based management 2018
 
Non immune hydrops latest
Non immune hydrops latestNon immune hydrops latest
Non immune hydrops latest
 
preterm labour
preterm labourpreterm labour
preterm labour
 
Adolescent gynecology ucaya
Adolescent gynecology ucayaAdolescent gynecology ucaya
Adolescent gynecology ucaya
 
Doppler interpretation in pregnancy
Doppler interpretation in pregnancyDoppler interpretation in pregnancy
Doppler interpretation in pregnancy
 
IUGR boom&fnd latest
IUGR boom&fnd latestIUGR boom&fnd latest
IUGR boom&fnd latest
 
First trimester ultrasound Dr. Muhammad Bin Zulfiqar
First trimester ultrasound Dr. Muhammad Bin ZulfiqarFirst trimester ultrasound Dr. Muhammad Bin Zulfiqar
First trimester ultrasound Dr. Muhammad Bin Zulfiqar
 
Single umbilical artery
Single umbilical arterySingle umbilical artery
Single umbilical artery
 
Overview of IUGR FGR
Overview of IUGR FGROverview of IUGR FGR
Overview of IUGR FGR
 
Intrauterine growth restriction
Intrauterine growth restrictionIntrauterine growth restriction
Intrauterine growth restriction
 
PLACENTA ACCRETA
PLACENTA ACCRETAPLACENTA ACCRETA
PLACENTA ACCRETA
 
Iugr and sga
Iugr and sgaIugr and sga
Iugr and sga
 
Antepartum and intrapartum foetal monitoring
Antepartum and intrapartum foetal monitoringAntepartum and intrapartum foetal monitoring
Antepartum and intrapartum foetal monitoring
 
First trimester scan
First trimester scanFirst trimester scan
First trimester scan
 

Similar to Iugr by dr derar ismerat

IUGR PPT.pptx
IUGR PPT.pptxIUGR PPT.pptx
IUGR PPT.pptx
ArvindJakhar5
 
iugr-180818145504 (1).pdf
iugr-180818145504 (1).pdfiugr-180818145504 (1).pdf
iugr-180818145504 (1).pdf
Monikashankar
 
Intrauterine growth retardation (IUGR)
Intrauterine growth retardation (IUGR)Intrauterine growth retardation (IUGR)
Intrauterine growth retardation (IUGR)
Summu Thakur
 
IUGR.pptx
IUGR.pptxIUGR.pptx
IUGR.pptx
Anju Kumawat
 
IUGR
IUGRIUGR
Approach to Intrauterine growth restriction
Approach to Intrauterine growth restrictionApproach to Intrauterine growth restriction
Approach to Intrauterine growth restriction
Dr. Habibur Rahim
 
Dilemmas in Diagnosis and Management of FGR Dr NNC 06082022.pptx
Dilemmas in Diagnosis and Management of FGR Dr NNC 06082022.pptxDilemmas in Diagnosis and Management of FGR Dr NNC 06082022.pptx
Dilemmas in Diagnosis and Management of FGR Dr NNC 06082022.pptx
Niranjan Chavan
 
Macrosomia and iugr with case study for undergraduare
Macrosomia and iugr with case study for undergraduareMacrosomia and iugr with case study for undergraduare
Macrosomia and iugr with case study for undergraduare
Faculty of Medicine,Zagazig University,EGYPT
 
IUGR
IUGRIUGR
Fetal Growth Restriction.pptx
Fetal Growth Restriction.pptxFetal Growth Restriction.pptx
Fetal Growth Restriction.pptx
RAHULSUTHAR46
 
IUGR.pptx
IUGR.pptxIUGR.pptx
IUGR.pptx
Robenus
 
Oligohydramnios and IUGR
Oligohydramnios and IUGROligohydramnios and IUGR
Oligohydramnios and IUGR
Tracy40
 
Intrauterine growth restriction (IUGR).pptx
Intrauterine growth restriction (IUGR).pptxIntrauterine growth restriction (IUGR).pptx
Intrauterine growth restriction (IUGR).pptx
Anju Kumawat
 
Foetal assessment11
Foetal assessment11Foetal assessment11
Foetal assessment11
P V GREESHMA
 
Fetal Growth Restriction.pptx
Fetal Growth Restriction.pptxFetal Growth Restriction.pptx
Fetal Growth Restriction.pptx
Anchal265129
 
Iugr vld
Iugr vldIugr vld
Iugr vld
Varsha Deshmukh
 
IUGR.pptx
IUGR.pptxIUGR.pptx
IUGR.pptx
jyotisingh511183
 
Fetal381503888-Fetal-Growth-Disorders.ppt
Fetal381503888-Fetal-Growth-Disorders.pptFetal381503888-Fetal-Growth-Disorders.ppt
Fetal381503888-Fetal-Growth-Disorders.ppt
Abdelrhman abooda
 
F.G.R. PANEL DISCUSSION AT FOGSI BOH CONFERENCE
F.G.R. PANEL DISCUSSION AT FOGSI BOH CONFERENCEF.G.R. PANEL DISCUSSION AT FOGSI BOH CONFERENCE
F.G.R. PANEL DISCUSSION AT FOGSI BOH CONFERENCE
NARENDRA MALHOTRA
 

Similar to Iugr by dr derar ismerat (20)

IUGR PPT.pptx
IUGR PPT.pptxIUGR PPT.pptx
IUGR PPT.pptx
 
iugr-180818145504 (1).pdf
iugr-180818145504 (1).pdfiugr-180818145504 (1).pdf
iugr-180818145504 (1).pdf
 
Intrauterine growth retardation (IUGR)
Intrauterine growth retardation (IUGR)Intrauterine growth retardation (IUGR)
Intrauterine growth retardation (IUGR)
 
IUGR.pptx
IUGR.pptxIUGR.pptx
IUGR.pptx
 
IUGR
IUGRIUGR
IUGR
 
Approach to Intrauterine growth restriction
Approach to Intrauterine growth restrictionApproach to Intrauterine growth restriction
Approach to Intrauterine growth restriction
 
Dilemmas in Diagnosis and Management of FGR Dr NNC 06082022.pptx
Dilemmas in Diagnosis and Management of FGR Dr NNC 06082022.pptxDilemmas in Diagnosis and Management of FGR Dr NNC 06082022.pptx
Dilemmas in Diagnosis and Management of FGR Dr NNC 06082022.pptx
 
Macrosomia and iugr with case study for undergraduare
Macrosomia and iugr with case study for undergraduareMacrosomia and iugr with case study for undergraduare
Macrosomia and iugr with case study for undergraduare
 
IUGR
IUGRIUGR
IUGR
 
Fetal Growth Restriction.pptx
Fetal Growth Restriction.pptxFetal Growth Restriction.pptx
Fetal Growth Restriction.pptx
 
IUGR.pptx
IUGR.pptxIUGR.pptx
IUGR.pptx
 
Oligohydramnios and IUGR
Oligohydramnios and IUGROligohydramnios and IUGR
Oligohydramnios and IUGR
 
Intrauterine growth restriction (IUGR).pptx
Intrauterine growth restriction (IUGR).pptxIntrauterine growth restriction (IUGR).pptx
Intrauterine growth restriction (IUGR).pptx
 
Foetal assessment11
Foetal assessment11Foetal assessment11
Foetal assessment11
 
Fetal Growth Restriction.pptx
Fetal Growth Restriction.pptxFetal Growth Restriction.pptx
Fetal Growth Restriction.pptx
 
Iugr vld
Iugr vldIugr vld
Iugr vld
 
Iugr obs
Iugr obsIugr obs
Iugr obs
 
IUGR.pptx
IUGR.pptxIUGR.pptx
IUGR.pptx
 
Fetal381503888-Fetal-Growth-Disorders.ppt
Fetal381503888-Fetal-Growth-Disorders.pptFetal381503888-Fetal-Growth-Disorders.ppt
Fetal381503888-Fetal-Growth-Disorders.ppt
 
F.G.R. PANEL DISCUSSION AT FOGSI BOH CONFERENCE
F.G.R. PANEL DISCUSSION AT FOGSI BOH CONFERENCEF.G.R. PANEL DISCUSSION AT FOGSI BOH CONFERENCE
F.G.R. PANEL DISCUSSION AT FOGSI BOH CONFERENCE
 

Recently uploaded

Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
VarunMahajani
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
Dr. Rabia Inam Gandapore
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
Savita Shen $i11
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Oleg Kshivets
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
Dr. Vinay Pareek
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
MedicoseAcademics
 
Antiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptxAntiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptx
Rohit chaurpagar
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
د.محمود نجيب
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
GL Anaacs
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
aljamhori teaching hospital
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
bkling
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
KafrELShiekh University
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
Krishan Murari
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
pal078100
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
kevinkariuki227
 
The Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of IIThe Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of II
MedicoseAcademics
 
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in StockFactory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
rebeccabio
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
NephroTube - Dr.Gawad
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Savita Shen $i11
 

Recently uploaded (20)

Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
 
Antiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptxAntiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptx
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
 
The Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of IIThe Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of II
 
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in StockFactory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
 

Iugr by dr derar ismerat

  • 1. INTRAUTERINE GROWTH RESTRICTION PRESENTED AND PREPARED BY DR . DERAR I . I . ISMERAT OBSTETRICS AND GYNECOLOGY RESIDENT DOCTOR AT AL-AHLI HOSPITAL
  • 2.
  • 3. Intrauterine growth restriction (IUGR) is a poorly understood complication of pregnancy, affecting up to 10% of live-born infants. It is characterized as a rate of fetal growth less than normal for the gestational-age appropriate growth potential Quantitatively, this poor fetal growth has been defined by the American College of Obstetricians and Gynecologists as estimated fetal weight of <10th percentile for gestational age, often times with ultrasound evidence of growth deceleration late in gestation or abnormal Doppler indexes in the umbilical artery or middle cerebral artery.
  • 4. Fetal growth restriction, (IUGR), is a common complication of pregnancy. • Pathologic condition where there is a restriction of growth in utero, and the fetus does not attain its full growth potential. • Complicates ≈5-10% of pregnancies • Third leading cause of perinatal mortality after anomalies and prematurity Perinatal mortality inversely proportional to percentile growth: 1.5% <10% 2.5% < 5th %
  • 5.
  • 6. Correlation of birth weight percentile to perinatal morbdity and mortalility
  • 7. IUGR (Intrauterine Growth Restriction) SGA (Small for Gestation Age) 30% babies with birthweight <10th percentile 70% babies with birthweight <10th percentile Growth restricted Not growth restricted Constitutionally and anatomically abnormal Constitutionally small but anatomically normal ↑ Obstetric/neonatal risk NO obstetric/neonatal risk {Variable} Normal subcutaneous fat
  • 8. • Stage I (Hyperplasia) • - 4 to 20 weeks • - Rapid mitosis • - Increase of DNAcontent • Stage II (Hyperplasia & Hypertrophy) • - 20 to 28 weeks • - Declining mitosis. • - Increase in cell size. • Stage III ( Hypertrophy) - 28 to 40 weeks - Rapid increase in cell size. - Rapid accumulation of fat, muscle and connective tissue. • 95% of fetal weight gain occurs during last 20 weeks of gestations.
  • 9. • 15 weeks = 5 grams/day • 20 weeks = 10 grams/day • 30 weeks = 25 grams/day • 35 weeks = 35 grams/day • 40 weeks = 15 grams/day • May vary by race, gender, multiple gestation
  • 10. Reduce fetal growth support.. EXTRINSIC CAUSES Reduce fetal growth potential.. INTRINSIC CAUSES PALCENTAL FACTORS MATERNAL FACTORS ANEUPLOIDY INTRA UTERINE INFECTION More morbidities and mortalities More long term effects
  • 11.
  • 12. Infection  CMV, Rubella, Toxoplasma gondii – severe IUGR  Syphilis, Tuberculosis, Malaria, listeriosis  Herpes simplex, chicken pox Chromosomal abnormality  Trisomy 18,13 –severe IUGR  Trisomy 21  Turner syndrome (45,XO(  Klinefelter syndrome (47,XXY( Congenital anomalies  Congenital Heart diseases  Anencephaly
  • 13. • Maternal malnutrition • Poor maternal weight gain • Severe anemia • Chronic hypoxemia • Cardiovascular disease • Drugs and teratogens • Multiple pregnancy • Antiphospholipid antibodies syndrome
  • 14. • Placental infarction • Placental abruption • Twin-twin transfusion syndrome • Placenta previa , circumvallate placenta • Marginal or velamentous insertion of umbilical cord
  • 15. : proposed in 1990 by the British epidemiologist David Barker (b. 1939) that intrauterine growth retardation will increase :. • Increased risk of adult metabolic syndrome • Obesity • Type 2 diabetes mellitus • Coronary artery disease • Stroke • Up to 50% cognitive disability • Increased risk of cerebral palsy • <10th percentile at 8 years • Early IUGR less likely to catch up
  • 16. • Clinical assessment • Ultrasonic measurement • Doppler velocity
  • 17. – Teen age – High altitude – Socioeconomic factor – Smoking , Alcohol , Drugs – Previous IUGR pregnancy history – previous IUGR in family
  • 18. Seldom elicited before 28 weeks of gestation: . Failure of fetus and uterus to grow at the normal rate over a 4 week period; .Uterine fundal height should be at least 2cm less than expected for the length of gestation; .Poor maternal weight gain; . Diminished fetal movements.
  • 19. Uterine fundal height  Uterine fundus  symphysis Pubic  Simple, Safe, Inexpensive for screening  Between 18 and 30 weeks,  the uterine fundal height in centimeters coincides with weeks of gestation.  If the measurement is more than 2 to 3 cm from the expected height or < 1oth percentile from normal curve, inappropriate fetal growth may be suspected
  • 20.  Inter-observer variations  Obese patients  Transverse lie  Multiple gestation  Polyhydramnios / Oligohydram  Uterine fibroids nios
  • 21. Initial U/S at 16 to 20 weeks to establish gestational age and identify anomalies and repeated at 32 to 34 weeks to evaluate fetal growth
  • 22. The measurements most commonly used to measure and follow fetal growth are: Biparietal Diameter HeadCircumference Femur Length Abdominal Circumference Used between 15-42 weeks. Normal ratio: <36 weeks = 1:1 >36 weeks - ratio decreases as the AC increases.
  • 23. Mild IUGR – Normal amniotic fluid Severe IUGR – Oligohydramnios (AFI is ≤ 5) Incidence 40%
  • 24. • Blood flowing through the umbilical arteries originates from the fetus and enters the placenta. • The flow of blood through the arteries is dependent upon the strength of the fetal heart contraction and the health of the placenta. • Blood returning from the placenta goes throughthe umbilical vein to the fetus.
  • 25. • Doppler principle based on changes in sound waves related to the flow velocity of blood traveling through these vessels. • The umbilical artery was first used to study this flow velocity in in 1977. • The umbilical arterial waveform usually has a "saw tooth" type pattern with flow always in the forward direction •The umbilical artery is evaluated by measuring the blood flow velocity at peak systole (maximal contraction of the heart) and peak diastole (maximal relaxation of the heart). • These values are then computed to derive a ratio.
  • 26. • As GA advances, increase blood flow at diastole means placenta less resistant.
  • 27. • In growth-retarded fetuses and fetuses developing intra- uterine distress, there is more placental resistance and the umbilical artery blood velocity waveform usually changes in a progressive manner. • Increased resistance, absent end diastolic flow, reverse flow. • Increasing RI values and S:D ratios if blood flow during diastole is decreased.
  • 28. • Absent End Diastolic flow
  • 29. • reversal of end diastolic flow (REDF)
  • 30. • notching in late in pregnancy is an indicator of increased uterine vascular resistance and impaired uterine circulation’
  • 31. : – characterized by absent or reversed end-diastolic flow – associated with fetal growth restriction A. Normal velocimetry pattern with an S/D ratio of < 3.0 B. The diastolic velocity approaching zero reflects increased placental vascular resistance. C. During diastole, arterial flow is reversed (negative S/D ratio), which is an ominous sign precede fetal demise
  • 32. Hypothermia? Hypoglycemia? Or Hypocalcemia? decreased subcutaneous fat, increased surface- volume ratio, decreased heat production decreased glycogen stores/ glycogenolysis/ gluconeogenesis increased metabolic rate deficient catecholamine release Associated with perinatal stress, asphyxia, prematurity
  • 33. Prepregnancy: to prevent it by identifying risk factors and treat as necessary (e.g. improve nutrition intake, stop smoking or alcohol, ASA in APA syndrome, and Heparin in thrombophilias) Antepartum: identify risk factors that can be changed. Fetal surveillance by ultrasound (BPP) and fetal heart monitoring (Non-Stress Test). To decide on timing and mode of delivery.
  • 34. Near term  Prompt delivery Recommend delivery at 34 weeks or beyond if there is clinically significant oligohydramnios • Growth Restriction Intervention Trial • Only published randomized trial to assess the timing of delivery of the early preterm (less than 34 weeks of gestation) growth-restricted fetus. • Randomized to either the early delivery group (delivery within 48 hours) or to the expectant management group (with antepartum surveillance until it was felt that delivery should not be delayed any longer) • Betamethasone administration were the same in both groups
  • 35. • Prospective Observational Trial to Optimize Pediatric Health in Intrauterine Growth Restriction (IUGR) (PORTO STUDY) • National prospective observational multicenter study • Evaluate which sonographic findings were associated with perinatal morbidity and mortality in pregnancies affected by growth restriction (defined as estimated fetal weight (EFW) <10th centile) • Am J Obstet Gynecol. 2013Apr;208(4)
  • 36. • STUDY DESIGN: • Over 1100 consecutive ultrasound-dated singleton pregnancies with EFW <10th centile were recruited from January 2010 through June 2012. • A range of IUGR definitions were used, including EFW orabdominal circumference <10th, <5th, or <3rd centiles • with or without oligohydramnios • with or without abnormal umbilical arterial Doppler • Adverse perinatal outcomes included intraventricular hemorrhage, periventricular leukomalacia, hypoxic ischemic encephalopathy, necrotizing enterocolitis, bronchopulmonary dysplasia, sepsis, and death • Am J Obstet Gynecol. 2013Apr;208(4)
  • 37. • RESULTS: • N=1116 fetuses • 312 (28%) were admitted to neonatal intensive care unit • 58 (5.2%) were affected by adverse perinatal outcome including 8 mortalities (0.7%) • The presence of abnormal umbilical Doppler was significantly associated with adverse outcome, irrespective of EFW or abdominal circumference measurement. • The only sonographic weight-related definition consistently associated with adverse outcome was EFW <3rd centile (P = .0131), all mortalities had EFW <3rd centile. • Presence of oligohydramnios was clinically important when combined with EFW <3rd centile (P = .0066). • Am J Obstet Gynecol. 2013 Apr;208(4)
  • 38. • CONCLUSION: • Abnormal umbilical artery Doppler and EFW <3rd centile were strongly and most consistently associated with adverse perinatal outcome. • Stricter IUGR cutoffs may be warranted and future studies should comparing various definitions of IUGR and management strategies
  • 39. • Management • Serial US q 2-4 weeks is indicated • Antenatal surveillance with umbilical artery Doppler velocimetry and antepartum testing (NST,BPP) • Delivery depends on the underlying etiology and estimated gestational age • Eunice Kennedy Shriver National Institute of Child Health and Human Development/Society for Maternal-Fetal Medicine/American College of Obstetricians and Gynecologists Joint Conference • Dx fetal growth restriction: • Delivery at 38 0/7–39 6/7 weeks of gestation isolated fetal growth restriction • Delivery at 34 0/7–37 6/7 weeks of gestation in cases of fetal growth restriction with additional risk factors for adverse outcome (eg, oligohydramnios, abnormal umbilical artery Doppler velocimetry results, maternal risk factors, or co- morbidities)
  • 40. • Delivery for fetal growth restriction before 34 weeks: • Planned at a center with a neonatal intensive care unit and consultation with a maternal–fetal specialist. • Antenatal corticosteroids should be administered • For cases in which delivery occurs before 32 weeks: • Magnesium sulfate should be considered for fetal and neonatal neuroprotection.
  • 41.
  • 42. • Heads are disproportionately large for their trunks and extremities • Facial appearance has been likened to that of a “wizened old man”. • Long nails. • Scaphoid abdomen
  • 43. • Way of characterizing the relationship of height to mass for an individual. • PI = 1000 x cubed root of Mass (kgs) Height (cms) • Typical values are 20 to 25. • PI is normal in symmetric IUGR. • PI is low in asymmetric IUGR